Birznieks Gunther's Form 4 filing
Vanda Pharmaceuticals Inc. (VNDA) · filed Mar 2, 2022
- Accession no.
- 0001209191-22-015154
- Filed
- Mar 2, 2022
- Trade date
- Feb 28-Mar 2, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $175.5K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Birznieks GuntherCIK 0001702031 | Officer (SVP, Business Development) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 28, 2022 | Common Stock | AGrant or awardAcquired | +32,700 | $0.00 | $0 | 204,408 | Direct | |
| Mar 1, 2022 | Common Stock | SSaleDisposed | −4,084 | $11.19 | −$45,699.96 | 200,324 | Direct | |
| Mar 2, 2022 | Common Stock | SSaleDisposed | −11,517 | $11.27 | −$129,796.59 | 188,807 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 28, 2022 | Common Stock | AGrant or awardAcquired | +77,500 | $0.00 | $0 | 77,500 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.